RxDoctor Payments Data

Alan Jensen, MD

Internal Medicine · Omaha, NENPI 1053495614

Payments from drug & device makers

$3,337in general payments, 2019–2025

Across 171 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$689
  • Antares Pharma, Inc.$629
  • Sanofi-aventis U.S. LLC$493
  • Jazz Pharmaceuticals Inc.$214
  • Amgen$181
  • Avadel CNS Pharmaceuticals, LLC$137
  • plus $994 from 19 others

What the payments were for

  • Food & beverage$3,325100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,337 in reported general payments places this provider in the 85th percentile of 570 internal medicine providers in Nebraska.

See all internal medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$17,249
Medicare patients
47
Services billed
181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide26$28,856
Soliqua 100-33Insulin Glargine/Lixisenatide29$25,802
EliquisApixaban29$24,877
FarxigaDapagliflozin Propanediol11$13,565
XareltoRivaroxaban11$12,359
SymbicortBudesonide/Formoterol Fumarate35$9,239
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl44$6,700
Liothyronine Sodium82$4,740
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen84$2,282
Colesevelam Hcl17$2,075
Testosterone Cypionate26$1,438
Albuterol Sulfate HfaAlbuterol Sulfate45$1,326
Atorvastatin Calcium150$1,317
ValacyclovirValacyclovir Hcl23$1,152
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine36$1,113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$33$28,85626 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$493$25,80229 claims
AstraZenecaFarxiga, Symbicort$28$22,80446 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 570 internal medicine providers in Nebraska.

Other internal medicine in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →